Bottom Line: Looking down to completed larger Wave 2
Anebulo is a high-conviction, early-stage biotech play centered on a first-in-class pediatric cannabis intoxication antidote. With robust academic interest, regulatory validation, and a manageable burn rate, the company may unlock value if IV selonabant progresses successfully.
(Last Price 2.86): Lacking any evidence of a turn higher at the sloped resistance, there is scope lower evidence that Aneb is in a wave 3 correction towards 1.37 region.
Daily Update: Up against 1.57, Aneb to remain above key resistance of 2.16
Daily Update: Up against 1.57, Aneb to remain above key resistance of 2.16
